Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225803 | 0.99 | RBP4 (0.65) | RBP4ALDH1A1KDM4EHSD17B10HSD11B1 | |
| SCHEMBL3223950 | 0.89 | RBP4 (0.62) | RBP4ALDH1A1HSD11B1GAATRPV1 | |
| SCHEMBL3222359 | 0.83 | HSD11B1 (0.62) | RBP4HSD17B10HSD11B1GAATRPV1 | |
| SCHEMBL3213678 | 0.81 | RBP4 (0.60) | RBP4ALDH1A1HSD11B1GAATRPV1 | |
| SCHEMBL3776097 | 0.80 | HRH3 (0.64) | RBP4ALDH1A1KDM4EHSD11B1GAA | |
| SCHEMBL16690887 | 0.78 | RBP4 (1.00) | RBP4ALDH1A1HSD17B10HSD11B1GAA | |
| SCHEMBL3095680 | 0.78 | HSD11B1 (0.76) | RBP4HSD11B1GAATRPV1TRPA1 | |
| SCHEMBL3771811 | 0.78 | HRH3 (0.67) | RBP4ALDH1A1HSD11B1GAATRPV1 | |
| SCHEMBL3219575 | 0.78 | GAA (0.60) | RBP4ALDH1A1HSD11B1GAATRPV1 | |
| SCHEMBL6988200 | 0.77 | HSD11B1 (0.70) | RBP4HSD17B10HSD11B1GAATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| CN-101400653-A | 11-beta HSD1 inhibitors | WYETH CORP (US) | 2009-04-01 | — | — | CN | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | RBP4 2175/4885ALDH1A1 116/4885KDM4E 1296/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | RBP4 2329/4885ALDH1A1 123/4885KDM4E 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.